United Capital Management of KS Inc. Has $5.46 Million Holdings in Intuitive Surgical, Inc. $ISRG

Key Points

• United Capital Management of KS Inc. has significantly increased its holdings in Intuitive Surgical, raising its position by 1,354.0% to own 11,021 shares, valued at approximately $5.46 million.
• Intuitive Surgical recently reported Q2 earnings of $2.19 per share, surpassing expectations and reflecting a year-over-year revenue increase of 21.4% to $2.44 billion.
• An insider, EVP Myriam Curet, sold 4,500 shares of the company stock, representing a 92.73% decrease in their ownership, raising concerns about insider confidence.

United Capital Management of KS Inc. increased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 1,354.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,021 shares of the medical equipment provider's stock after buying an additional 10,263 shares during the period. United Capital Management of KS Inc.'s holdings in Intuitive Surgical were worth $5,458,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Parvin Asset Management LLC bought a new stake in Intuitive Surgical during the fourth quarter valued at $26,000. Chilton Capital Management LLC boosted its holdings in shares of Intuitive Surgical by 614.3% during the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 43 shares during the period. Global Financial Private Client LLC boosted its holdings in shares of Intuitive Surgical by 253.3% during the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock valued at $26,000 after acquiring an additional 38 shares during the period. Elite Financial Inc. acquired a new position in shares of Intuitive Surgical during the first quarter valued at $26,000. Finally, LFA Lugano Financial Advisors SA acquired a new position in shares of Intuitive Surgical during the first quarter valued at $30,000. Institutional investors own 83.64% of the company's stock.

Intuitive Surgical Stock Performance

NASDAQ ISRG traded up $3.18 on Friday, reaching $480.26. The company's stock had a trading volume of 1,436,064 shares, compared to its average volume of 2,169,233. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $616.00. The stock has a market cap of $172.16 billion, a PE ratio of 66.98, a PEG ratio of 5.03 and a beta of 1.59. The firm's 50 day moving average is $508.75 and its two-hundred day moving average is $524.77.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The company had revenue of $2.44 billion during the quarter, compared to the consensus estimate of $2.35 billion. During the same period in the prior year, the company earned $1.78 EPS. Intuitive Surgical's revenue was up 21.4% on a year-over-year basis. Equities research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Analyst Ratings Changes

ISRG has been the subject of several analyst reports. Citigroup reissued a "buy" rating and set a $650.00 price target (up previously from $590.00) on shares of Intuitive Surgical in a report on Thursday, May 22nd. Wall Street Zen raised shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Truist Financial boosted their price target on shares of Intuitive Surgical from $590.00 to $600.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. UBS Group boosted their price target on shares of Intuitive Surgical from $547.00 to $585.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Finally, Evercore ISI boosted their price target on shares of Intuitive Surgical from $470.00 to $550.00 and gave the company an "in-line" rating in a report on Tuesday, July 8th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $595.95.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Myriam Curet sold 4,500 shares of the business's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the sale, the executive vice president owned 353 shares in the company, valued at approximately $173,845.44. The trade was a 92.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gary S. Guthart sold 2,800 shares of the business's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $495.24, for a total value of $1,386,672.00. Following the sale, the insider owned 18,520 shares in the company, valued at approximately $9,171,844.80. The trade was a 13.13% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 15,839 shares of company stock valued at $7,896,972. 0.70% of the stock is owned by insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.